The cumulative export sales of Dong-A ST’s biosimilar anemia treatment have exceeded 10 billion won. After entering the Japanese market through a partner company at the end of 2019, the sales of Dong-A ST's biosimilar have shown steady growth based on the increasing product recognition and favorable policies set on biosimilars by the Japanese government.

According to Dong-A ST on the 1st, its overseas sales of ‘Darbepoetin-alfa’ during the first quarter of this year was 2.9 billion won, a 326.6% increase from the same period of the previous year.

‘Darbepoetin-alfa’ is a biosimilar of the second generation anemia treatment ‘Nesp (darbepoetin-α)’ that was co-developed by Am